We analyzed data from a randomized trial of AIK-C, high-titre (EZ-H) or medium-titre EZ (EZ-M) vaccines in 3.5 and 6 month old infants in Kinshasa.
Zaire, in which the occurrence of rhinorrhoea, cough, diarrhoea, fever, conjunctivitis or rash was monitored for IS days post-vaccination (including the day of vaccination, day 0).
We compared sero-response at 6 weeks and 6 months post-vaccination among children with and without mild illness at or after vaccination.
Seroresponse tended to be higher in children with mild illness after vaccination than those without, whether days 0-7 or 8-15 were examined.
For most symptoms, these differences did not reach statistical significance after adjusting for prevaccination maternal antibody level.
However, in the EZ-M group, the proportion of children attaining at least the median post-vaccination antibody level was significantly higher in children with rhinorrhoea in days 0-7 post-vaccination than those without (adjusted odds ratio 2.6,95% Cl 1.08 6.27), as was that among children with at least one symptom in days 0-7 compared with children with no symptoms (adjusted OR 4.55,95% CI 1.18-17.57).
There were no significant differences in post-vaccination antibody levels among children with symptoms compared either to those without the specific symptom or those with no symptoms.
Fever on the day of vaccination or at home visits on 7.10 or 14 days post-vaccination, did not affect seroconversion or GMTs. (...)
Mots-clés Pascal : Virus rougeole, Morbillivirus, Paramyxovirinae, Paramyxoviridae, Mononegavirales, Virus, Nourrisson, Homme, Rougeole, Virose, Infection, Vaccination, Voie souscutanée, Immunogénicité, Réponse immune, Relation dose réponse, Rappel vaccination, Age, Symptomatologie, Programme sanitaire, Pays en développement, Congo(République démocratique), Afrique, Afrique Centrale
Mots-clés Pascal anglais : Measles virus, Morbillivirus, Paramyxovirinae, Paramyxoviridae, Mononegavirales, Virus, Infant, Human, Measles, Viral disease, Infection, Vaccination, Subcutaneous administration, Immunogenicity, Immune response, Dose activity relation, Booster vaccination, Age, Symptomatology, Sanitary program, Developing countries, Congo(Democratic republic), Africa, Central Africa
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0188585
Code Inist : 002B05A02. Création : 16/11/1999.